154 related articles for article (PubMed ID: 34452709)
1. Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs.
van Oostrum I; Ouwens M; Remiro-Azócar A; Baio G; Postma MJ; Buskens E; Heeg B
Value Health; 2021 Sep; 24(9):1294-1301. PubMed ID: 34452709
[TBL] [Abstract][Full Text] [Related]
2. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
Bullement A; Meng Y; Cooper M; Lee D; Harding TL; O'Regan C; Aguiar-Ibanez R
J Med Econ; 2019 Mar; 22(3):205-214. PubMed ID: 30422080
[TBL] [Abstract][Full Text] [Related]
3. Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial.
Sweeting MJ; Rutherford MJ; Jackson D; Lee S; Latimer NR; Hettle R; Lambert PC
Med Decis Making; 2023 Aug; 43(6):737-748. PubMed ID: 37448102
[TBL] [Abstract][Full Text] [Related]
4. Blended Survival Curves: A New Approach to Extrapolation for Time-to-Event Outcomes from Clinical Trials in Health Technology Assessment.
Che Z; Green N; Baio G
Med Decis Making; 2023 Apr; 43(3):299-310. PubMed ID: 36314662
[TBL] [Abstract][Full Text] [Related]
5. Extrapolating Parametric Survival Models in Health Technology Assessment: A Simulation Study.
Gallacher D; Kimani P; Stallard N
Med Decis Making; 2021 Jan; 41(1):37-50. PubMed ID: 33283635
[TBL] [Abstract][Full Text] [Related]
6. Extrapolating Survival Data Using Historical Trial-Based a Priori Distributions.
Soikkeli F; Hashim M; Ouwens M; Postma M; Heeg B
Value Health; 2019 Sep; 22(9):1012-1017. PubMed ID: 31511177
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making.
Tai TA; Latimer NR; Benedict Á; Kiss Z; Nikolaou A
Value Health; 2021 Apr; 24(4):505-512. PubMed ID: 33840428
[TBL] [Abstract][Full Text] [Related]
8. How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017.
Gallacher D; Auguste P; Connock M
Int J Technol Assess Health Care; 2019 Jan; 35(2):160-167. PubMed ID: 31017564
[TBL] [Abstract][Full Text] [Related]
9. SurvInt: a simple tool to obtain precise parametric survival extrapolations.
Gallacher D
BMC Med Inform Decis Mak; 2024 Mar; 24(1):76. PubMed ID: 38486175
[TBL] [Abstract][Full Text] [Related]
10. Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer.
Gray J; Sullivan T; Latimer NR; Salter A; Sorich MJ; Ward RL; Karnon J
Med Decis Making; 2021 Feb; 41(2):179-193. PubMed ID: 33349137
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause Survival.
Lee S; Lambert PC; Sweeting MJ; Latimer NR; Rutherford MJ
Value Health; 2024 Jan; 27(1):51-60. PubMed ID: 37858887
[TBL] [Abstract][Full Text] [Related]
12. Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations.
Ouwens MJNM; Mukhopadhyay P; Zhang Y; Huang M; Latimer N; Briggs A
Pharmacoeconomics; 2019 Sep; 37(9):1129-1138. PubMed ID: 31102143
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis.
Djalalov S; Beca J; Ewara EM; Hoch JS
Pharmacoeconomics; 2019 Dec; 37(12):1525-1536. PubMed ID: 31571137
[TBL] [Abstract][Full Text] [Related]
14. Assessing the Performance of Alternative Methods for Estimating Long-Term Survival Benefit of Immuno-oncology Therapies.
Monnickendam G
Value Health; 2024 Jun; 27(6):746-754. PubMed ID: 38428815
[TBL] [Abstract][Full Text] [Related]
15. Direct Incorporation of Expert Opinion into Parametric Survival Models to Inform Survival Extrapolation.
Cooney P; White A
Med Decis Making; 2023 Apr; 43(3):325-336. PubMed ID: 36647200
[TBL] [Abstract][Full Text] [Related]
16. Application of dynamic modeling for survival estimation in advanced renal cell carcinoma.
Deniz B; Altincatal A; Ambavane A; Rao S; Doan J; Malcolm B; Michaelson MD; Yang S
PLoS One; 2018; 13(8):e0203406. PubMed ID: 30161244
[TBL] [Abstract][Full Text] [Related]
17. Extending Beyond Bagust and Beale: Fully Parametric Piecewise Exponential Models for Extrapolation of Survival Outcomes in Health Technology Assessment.
Cooney P; White A
Value Health; 2023 Oct; 26(10):1510-1517. PubMed ID: 37353057
[TBL] [Abstract][Full Text] [Related]
18. A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement.
Bell Gorrod H; Kearns B; Stevens J; Thokala P; Labeit A; Latimer N; Tyas D; Sowdani A
Med Decis Making; 2019 Nov; 39(8):899-909. PubMed ID: 31707911
[No Abstract] [Full Text] [Related]
19. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
[TBL] [Abstract][Full Text] [Related]
20. How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness.
Kearns B; Stevens J; Ren S; Brennan A
Pharmacoeconomics; 2020 Feb; 38(2):193-204. PubMed ID: 31761997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
